Pensionfund Sabic Purchases Shares of 18,000 CVS Health Corporation $CVS

Pensionfund Sabic purchased a new stake in CVS Health Corporation (NYSE:CVS) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 18,000 shares of the pharmacy operator’s stock, valued at approximately $1,428,000.

Other institutional investors have also made changes to their positions in the company. Norges Bank bought a new position in CVS Health in the second quarter valued at $1,358,698,000. Wellington Management Group LLP grew its holdings in shares of CVS Health by 391.6% in the 3rd quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock valued at $477,273,000 after acquiring an additional 5,042,816 shares in the last quarter. Amundi increased its position in shares of CVS Health by 95.3% in the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after acquiring an additional 3,637,943 shares during the last quarter. Invesco Ltd. increased its position in shares of CVS Health by 15.3% in the second quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock valued at $1,623,270,000 after acquiring an additional 3,118,626 shares during the last quarter. Finally, Capital Research Global Investors raised its holdings in CVS Health by 24.5% during the third quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after acquiring an additional 2,253,531 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Proposed FTC settlement on insulin pricing for Caremark eases a major legal overhang — CVS said it reached a proposed agreement with FTC staff covering its Caremark PBM unit (Caremark denies wrongdoing). The resolution reduces uncertainty around potential fines or structural remedies that could have been disruptive to PBM operations, and was the main constructive catalyst for the rally. CVS reaches insulin pricing settlement with FTC
• Positive Sentiment: Analyst upgrade supports sentiment — Bernstein upgraded CVS to Outperform (price target raised to ~$94), highlighting exposure to a Medicare Advantage turnaround and improving fundamentals; upgrades can draw buying interest from institutional investors. Bernstein Upgrades CVS Health (CVS) Stock to Outperform from Market Perform
• Neutral Sentiment: Health-care sector breadth provided tailwinds — the NYSE Health Care Index rose late in the session, lifting peers and creating a supportive macro backdrop for CVS. Sector momentum likely amplified the stock’s move. Sector Update: Health Care Stocks Advance Late Afternoon
• Neutral Sentiment: Technical bounce after multi-session weakness — coverage noted CVS rising after a six-session losing streak, which can attract short-term buyers and traders looking for mean reversion. CVS Health (CVS) Ascends While Market Falls: Some Facts to Note
• Negative Sentiment: State-level political pressure could create regulatory risk — reporting shows a Tennessee bill that would pit retail pharmacies against PBMs (potentially forcing CVS to choose between its stores and Caremark), and a local report flagged ~$479M in related spending; this raises the prospect of restrictive state laws or reputational risk. This bill could make CVS choose between its stores and its pharmacy benefit manager
• Negative Sentiment: Political/legal headline noise and potential compliance issues — coverage of CVS spending >$1M on ads to oppose the pharmacy bill and reporting that Tenn. AG says certain company texts could violate state law add short-term political and legal uncertainty that could pressure sentiment if escalated. CVS Health spends more than $1M on TV ads to block pharmacy bill Tenn. AG: CVS texts on pharmacy bill could violate state law
• Negative Sentiment: Critical articles highlight operational and valuation risks — some media pieces calling out risks in CVS’ business mix and recent share declines can reinforce cautious positioning among investors. 3 Reasons CVS is Risky and 1 Stock to Buy Instead

CVS Health Stock Up 2.1%

Shares of NYSE CVS opened at $72.80 on Wednesday. The company has a market cap of $92.61 billion, a price-to-earnings ratio of 52.75, a PEG ratio of 0.74 and a beta of 0.49. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The stock has a 50-day moving average price of $77.14 and a two-hundred day moving average price of $77.81. CVS Health Corporation has a 12 month low of $58.35 and a 12 month high of $85.15.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.09. The company had revenue of $105.69 billion during the quarter, compared to the consensus estimate of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm’s revenue was up 8.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd will be paid a $0.665 dividend. The ex-dividend date is Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 3.7%. CVS Health’s payout ratio is currently 192.75%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on CVS shares. UBS Group reaffirmed an “outperform” rating on shares of CVS Health in a research report on Wednesday, December 10th. Sanford C. Bernstein raised CVS Health from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $91.00 to $94.00 in a report on Thursday, March 12th. Bank of America dropped their price target on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a research report on Tuesday, January 27th. JPMorgan Chase & Co. boosted their price objective on shares of CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of CVS Health in a research note on Wednesday, December 10th. Twenty analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $95.05.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.